MicroCures is pleased to announce its strategic restructuring as a spinout of MicroCures Vision, creating two focused organizations to accelerate innovation in regenerative medicine.
MicroCures Vision will advance its lead program in neurotrophic keratitis (NK), including development of MCR-231, a pro-regenerative siRNA therapy targeting FL2 to restore natural healing in the eye.
This transition enables each organization to pursue its mission with greater clarity and momentum.